New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy

6533b850fe1ef96bd12a8507

RESEARCH PRODUCT

New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy

Félix Sancenón Virginia Merino Virginia Merino Isabel González-álvarez Marta González-álvarez María D. Marcos Adrián H. Teruel Ramón Martínez-máñez Marival Bermejo

subject

Colon Administration Oral Review 02 engineering and technology Disease Intestinal permeability Inflammatory bowel diseases Pharmacology 030226 pharmacology & pharmacy Inflammatory bowel disease Catalysis lcsh:Chemistry Inorganic Chemistry 03 medical and health sciences Drug Delivery Systems QUIMICA ORGANICA 0302 clinical medicine In vivo QUIMICA ANALITICA medicine Animals Humans Physical and Theoretical Chemistry Mesalamine Adverse effect lcsh:QH301-705.5 Molecular Biology Spectroscopy Intestinal permeability business.industry QUIMICA INORGANICA Organic Chemistry Inflammatory Bowel Diseases General Medicine Colitis 021001 nanoscience & nanotechnology medicine.disease Small intestine Computer Science Applications Aminosalicylic Acids Drug Liberation medicine.anatomical_structure lcsh:Biology (General)lcsh:QD1-999 Drug delivery Drug delivery 0210 nano-technology business

description

[EN] Colonic Drug Delivery Systems (CDDS) are especially advantageous for local treatment of inflammatory bowel diseases (IBD). Site-targeted drug release allows to obtain a high drug concentration in injured tissues and less systemic adverse effects, as consequence of less/null drug absorption in small intestine. This review focused on the reported contributions in the last four years to improve the effectiveness of treatments of inflammatory bowel diseases. The work concludes that there has been an increase in the development of CDDS in which pH, specific enzymes, reactive oxygen species (ROS), or a combination of all of these triggers the release. These delivery systems demonstrated a therapeutic improvement with fewer adverse effects. Future perspectives to the treatment of this disease include the elucidation of molecular basis of IBD diseases in order to design more specific treatments, and the performance of more in vivo assays to validate the specificity and stability of the obtained systems.

year	journal	country	edition	language
2020-09-01	International Journal of Molecular Sciences

https://doi.org/10.3390/ijms21186502